Register-Forschung in der Rheumatologie
PD Dr. med. Anne C. RegiererRegister-Forschung in der Rheumatologie
PD Dr. med. Anne C. Regierer
Scientific Career
Since 01/2024 Group Leader, Registry Research in Rheumatology, DRFZ
11/16-12/23 Deputy Group Leader, Pharmacoepidemiology, DRFZ
Since 04/15 German Rheumatism Research Centre, Berlin (DRFZ), Epidemiology Unit, Group Pharmacoepidemiology, Postdoctoral research fellow
2015 Habilitation and venia legendi, Charité, “Clinical health services research in breast cancer”
12/10-03/15 Research fellow and residency at the Dep. of Hematology and Oncology, Charité Berlin
12/09-11/10 Research fellow at the University of Bremen, Faculty of Mathematics and Computer Science, eScience Institute
08/02-11/09 Research fellow and residency at the Dep. of Hematology and Oncology, Charité Berlin
EDUCATION
2002 Doctoral thesis (Dr. med.), “Phenotypical and functional characterization of peripheral B-cells during wasp-venom immunotherapy”, Prof. Margitta Worm
1997-2002 Medical School at the Charité-Universitätsmedizin Berlin, Medical License
1995-1997 Medical School at the University of Hamburg
1993-1995 Faculty of Economics at the Alberts-Ludwigs-University of Freiburg
BOARDS and MEMBERSHIPS
Boards
Since 2023 Spokesperson, Working Group Medical Registries, TMF e.V.
Since 2021 European League Against Rheumatism-Task force: points to consider on the initiation of targeted therapies in patients with inflammatory arthritides and a recent history of cancer
Since 2020 Ad-hoc-commission of the COVID-19-Rheuma-Register of the German Society of Rheumatology
Since 2019 Advisory Board of the Biobank Fraunhofer Institute IME, Frankfurt
Since 2019 Steering Committee of the digital plattform project of BDRh, DRFZ, DGRh and
VRA (Rhemit)
Memberships
German Society for Rheumatology (DGRh)
German Network Health Service Research (DNVF)
German Society for Internal Medicine (DGIM)
AWARDS
2014 Charité scholarship “Rahel-Hirsch”
2014 Charité Mentoring programme
2008 Poster price of the German Society of Hematology and Oncology (DGHO)
THIRD PARTY FUNDING
2020-2024 TARISMA Targeted risk management in musculoskeletal diseases (BMBF grant)
Since 2017 RABBIT-SpA disease register for Spondyloarthritides (unconditional grant from industry consortium), ongoing
2012-2015 Research Grant, Gentechnologie-Stiftung Berlin
Project: Influence of CYP2D6-genotype on tamoxifen
Key Publications
- Reich, A., A. Weiss, L. Lindner, X. Baraliakos, D. Poddubnyy, S. Zinke, C. Stille, A. Strangfeld, C. Regierer. Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort. Arthritis Res Ther. 2023 Aug 2; 25(1):136.
- Machado PM, Schafer M, Mahil SK, Liew J, Gossec L, Dand N, et al. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Ann Rheum Dis. 2023 May; 82(5):698-709.
- Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, et al. Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases. RMD Open. 2023 Apr; 9(2).
- Regierer AC, Weiss A, Proft F, Baraliakos X, Behrens F, Poddubnyy D, et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA. RMD Open. 2023 Mar; 9(1).
- Albrecht K, Regierer AC, Strangfeld A, Marschall U, Callhoff J. High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex. RMD Open. 2023 Mar; 9(1).
- Regierer AC, Weiss A, Kiltz U, Sieper J, Schwarze I, Bohl-Buhler M, et al. The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study. J Rheumatol. 2023 Feb; 50(2):185-191.
- Albrecht K, Binder S, Minden K, Poddubnyy D, Regierer AC, Strangfeld A, Callhoff J. Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. Z Rheumatol. 2023 Feb 7.
- Regierer AC, Hasseli R, Schafer M, Hoyer BF, Krause A, Lorenz HM, et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 2021 Oct; 7(3).
- Lindner L, Weiß A, Reich A, Kindler S, Behrens F, Braun J, Listing J, Schett G, Sieper J, Strangfeld A, Regierer AC. Implementing an automated monitoring process in a digital, longitudinal observational cohort study. Arthritis Res Ther. 2021 Jul 7;23(1):181.
- Hasseli R, Pfeil A, Hoyer BF, Lorenz HM, Regierer AC, Richter JG, Schmeiser T, Strangfeld A, Voll RE, Krause A, Schulze-Koops H, Müller-Ladner U, Specker C. Deutsches Register www.Covid19-Rheuma.de : Statusbericht nach 1 Jahr der Pandemie [German registry www.Covid19-Rheuma.de: Status report after 1 year of the pandemic]. Z Rheumatol. 2021 Jul 1:1–6.
- Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Schäfer M, Schmeiser T, Strangfeld A, Schulze-Koops H, Voll RE, Specker C, Regierer AC. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021 Jan;7(1):e001464.
- Hasseli R, Mueller-Ladner U, Schmeiser T, Hoyer BF, Krause A, Lorenz HM, Regierer AC, Richter JG, Strangfeld A, Voll RE, Pfeil A, Schulze-Koops H, Specker C.: National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open 2020 Sep;6(2):e001332.
- Regierer AC, Weiß A, Baraliakos X, Zink A, Listing J, Strangfeld A.: RABBIT-SpA: ein neues Krankheitsregister für axiale Spondyloarthritis und Psoriasisarthritis. [RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis] Z Rheumatol. 2020 Mar;79(2):135-142.
- Mercer LK*, Regierer AC*, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J.: Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017 Dec;76(12):2025-2030.